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Background: Glucocorticoids are widely regarded as the most effective treatment for asthma. However, the direct
impact of glucocorticoids on the innate immune system and antibacterial host defense during asthma remain
unclear. Understanding the mechanisms underlying this process is critical to the clinical application of
glucocorticoids for asthma therapy. After sensitization and challenge with ovalbumin (OVA), BALB/c mice were
treated with inhaled budesonide and infected with Pseudomonas aeruginosa (P. aeruginosa). The number of viable
bacteria in enflamed lungs was evaluated, and levels of interleukin-4 (IL-4) and interferon-γ (IFN-γ) in serum were
measured. A lung epithelial cell line was pretreated with budesonide. Levels of cathelicidin-related antimicrobial
peptide (CRAMP) were measured by immunohistochemistry and western blot analysis. Intracellular bacteria were
observed in lung epithelial cells.
Results: Inhaled budesonide enhanced lung infection in allergic mice exposed to P. aeruginosa and increased the
number of viable bacteria in lung tissue. Higher levels of IL-4 and lower levels of IFN-γ were observed in the serum.
Budesonide decreased the expression of CRAMP, increased the number of internalized P. aeruginosa in OVA-
challenged mice and in lung epithelial cell lines. These data indicate that inhaled budesonide can suppress
pulmonary antibacterial host defense by down-regulating CRAMP in allergic inflammation mice and in cells in vitro.
Conclusions: Inhaled budesonide suppressed pulmonary antibacterial host defense in an asthmatic mouse model
and in lung epithelium cells in vitro. This effect was dependent on the down-regulation of CRAMP.
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Asthma is a chronic inflammatory disorder characterized
by airway inflammation and airway hyperresponsiveness.
Disease is mediated by increased levels of T-helper 2
(Th2) cytokines, interleukin (IL)-4, IL-5, and IL-13 and
elevated serum IgE [1]. The lungs are always exposed to
the environment and its microbial components. Infections* Correspondence: lzlgp@163.com
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Epidemiological investigations have indicated that allergic
asthma is a risk factor for pulmonary infection [2,3].
Patients with atopic asthma also develop more infections
than non-atopic individuals.
The innate immune system is the first line of host
defense. It is responsible for the immediate recognition
and regulation of microbial invasion. The innate im-
mune system consists of a range of pre-existing, rapidly
mobilized host cellular defenses, including neutrophils,
macrophages, epithelial cells, mast cells, eosinophils, and
natural killer cells [4]. Airway epithelial cells are an ac-
tive part of the innate pulmonary immune system and
are capable of recognizing microorganisms and secretingtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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antiviral proteins [5]. Antimicrobial peptides (AMPs)
have significant antimicrobial activity. Cathelicidins are
expressed in bone-marrow-derived and epithelial cells,
and have antimicrobial action against bacteria, viruses,
and fungi [6]. Low levels of cathelicidin expression can
increase susceptibility to infections [7,8]. Th2 cytokines
can inhibit antimicrobial host defense in individuals with
allergic diseases, and treatment for atopic dermatitis
with corticosteroids can cause a strong reduction in
AMP levels in both human skin and essential-fatty-acid-
deficient (EFAD) mice [9,10].
Glucocorticoids, which are widely regarded as the
most effective treatment for asthma, can inhibit the pro-
duction of most cytokines [11]. In chronic obstructive
pulmonary disease, inhaled corticosteroids can increase
the risk of pneumonia [12]. Although glucocorticoids
have a direct impact on the innate immune system, their
effect on asthma remains unclear. To determine the ef-
fect of budesonide on antibacterial host defense and al-
lergic airway inflammation, mice and a murine lung
epithelial cell line (MLE-12) were treated with budesonide
and infected with Pseudomonas aeruginosa. Our results
show that inhaled budesonide suppressed pulmonary anti-











Figure 1 Effects of budesonide on lung infection in mice exposed to
intraperitoneal injection with ovalbumin (OVA) in aluminum hydroxide on
challenged with OVA. OVA-challenged mice were treated with inhaled bud
were infected intranasally with 1 x 107 CFU ml-1 P. aeruginosa. Mice were k
with hematoxylin and eosin (HE) (original magnification ×200). OVA/Bud m
than OVA/No mice. However, OVA/Bud/P.a mice developed more inflammdown-regulation of cathelicidin-related antimicrobial pep-
tide (CRAMP).
Results
Effects of budesonide on lung inflammation upon
exposure to P. aeruginosa
Inhaled budesonide inhibits allergic airway inflamma-
tion, but the mechanisms involved in increased risk of
lung infection in asthmatic patients exposed to bacteria
remains unclear. Twenty-four hours after the last dose
of inhaled budesonide, histological analysis showed there
was less inflammatory infiltration in OVA-challenged
mice treated with budesonide (OVA/Bud) than in un-
treated OVA-challenged mice (OVA/No) (Figure 1B).
The cellular infiltration scores of OVA/Bud mice were
lower than those of OVA/No mice (Table 1).
This confirmed that inhaled budesonide inhibited al-
lergic airway inflammation in OVA/Bud mice. However,
we observed different results when mice were infected
with P. aeruginosa. After treatment with inhaled budeso-
nide, diffuse inflammatory cell infiltration and lung
abscesses were observed in OVA-challenged mice exposed
to P. aeruginosa (OVA/Bud/P.a). The cellular infiltration
scores of OVA/Bud/P.a mice were higher than those for





P. aeruginosa. A) Animal model. Mice were sensitized by
days 1 and 8. From days 15 through 22, mice were intranasally
esonide on days 23 through 30. On day 31, budesonide-treated mice
illed after 24 h of P. aeruginosa infection. B) Lung samples were stained
ice had less extensive infiltration of inflammatory cells in the airways
ation and cellular infiltration than OVA/P.a mice.
Table 1 The extent of lung inflammation were analyzed by microscopical histopathologic scoring 24 h after
intrartracheal challenge with P. aeruginosa
Treatment group No. of mice with the following lung pathology score/total no. of mice (%) Lungabscess incidence
1+2 3 4 (%)
Control 9/10(90) 1/10(10) 0 0
OVA 3/10(30) 6/10(60) 1/10(10) 10
OVA/P.a 0 7/10(70) 3/10(10) 30
ONA/BUD 7/10(70) 3/10(30) 0 0
OVA/BUD/P.a 0 3/10(30) 7/10(60)** 70**
The cellular infiltration scoring of OVA/Bud mice was lower than that in OVA. The scoring of OVA/Bud/P. a mice was higher than that in OVA/P. a *p<0.001
compared to OVA; **p<0.001 compared to OVA/.a.
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inflammation in OVA-challenged mice treated with inhaled
budesonide compared with untreated OVA-challenged
mice.AEffects of budesonide on bacterial levels in OVA-
challenged mice exposed to P. aeruginosa
To determine whether budesonide can increase the risk
of pulmonary infection in asthma patients, bacterial
levels in the lungs were determined 24 h after infection
of mice with P. aeruginosa. Higher numbers of bacterial
colony forming units (CFU) were observed in OVA/
Bud/P.a mice than in OVA/P.a mice (*P<0.05) (Figure 2).
The number of CFU in control mice, which received
phosphate-buffered saline (PBS) instead of active bac-
teria, was zero. These data show that inhaled budesonide
can reduce the clearance of P. aeruginosa and increase














Figure 2 Measurement of CFUs in lung homogenates by
quantitative culture of serial dilutions on blood agar plates.
Figure 2A represents the bacterial colonies on blood agar plates
between OVA/P.a mice and OVA/Bud/P.a mice observed using a
Kodak Image 4000MM. Figure 2B represents CFUs, shown in column
configuration. There were significantly more CFUs in OVA/Bud/P.a
mice than in OVA/P.a mice (*P<0.05). Control mice receiving PBS
only had no observable CFUs (0 CFU).Effects of budesonide on IL-4 in OVA-challenged mice
exposed to P. aeruginosa
Levels of IL-4 and interferon (IFN)-γ in the serum of
mice exposed to P. aeruginosa were detected to deter-
mine the relationship between inhaled budesonide and
Th1/Th2 immunoreactions for antibacterial host defense
during asthma. The levels of IL-4 in serum were lower
in OVA/Bud mice compared with those in OVA/No
mice (*P<0.01). However, the levels of IL-4 in OVA/Bud/
P.a mice were higher than those in OVA/P.a mice
(#P<0.01). IL-4 levels were lower in PBS control mice
(PBS) than in other mice (OVA/No, OVA/Bud and
OVA/Bud/P.a mice) (Figure 3). The level of IFN-γ in
OVA/Bud mice was not significantly different from that
of OVA/No mice (**P>0.05). There was also no signifi-
cant difference between levels of IFN-γ in OVA/Bud/P.a
mice and OVA/P.a mice (##P>0.05). IFN-γ levels were
lower in OVA/No, OVA/Bud, and OVA/Bud/P.a mice
compared with those in PBS control mice (PBS)
(P<0.01) (Figure 3). These data demonstrated that
inhaled budesonide could decrease IL-4 levels in OVA-challenged mice and that P. aeruginosa infection could
increase IL-4 levels in OVA/Bud/P.a mice.
Effects of budesonide on CRAMP in OVA-challenged mice
exposed to P. aeruginosa
Airway epithelial cells can be induced to secrete AMPs.
Whether inhaled budesonide can inhibit AMPs remains
unclear. In the present study, AMP was expressed in
epithelial cells of normal lungs and in epithelial cells and
inflammatory cells in OVA-challenged mouse lung tis-
sues (Figure 4A). CRAMP expression was significantly
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Figure 3 Serum levels of IL-4 and IFN-γ. Cytokines in serum were determined by ELISA after 24 h of P. aeruginosa infection. IL-4 was lower in
OVA/Bud mice than in OVA/No mice (*P<0.01). IL-4 in OVA/Bud/P.a mice was higher than in OVA/P.a mice (#P<0.01). IFN-γ in OVA/Bud mice was
not significantly different from that of OVA/No mice (**P>0.05). IFN-γ in OVA/Bud/P.a mice was not significantly different from that of OVA/P.a
mice (##P>0.05). IL-4 in PBS control mice was lower than in all other mice (OVA/No, OVA/Bud and OVA/Bud/P.a). IFN-γ in OVA/No, OVA/Bud, and
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Figure 4 Expression of CRAMP in lungs by immunohistochemistry and western blot analysis. A) CRAMP expression and localization in
lung tissues was determined by immunostaining (original magnification ×200). B) CRAMP expression in lung tissue was determined by western
blot analysis. C) Densitometry analysis of CRAMP in lung tissues. Both immunohistochemistry and western blot analysis showed that expression of
CRAMP in OVA/Bud/P.a mice was markedly lower than in OVA/P.a mice. CRAMP expression in PBS control mice was significantly lower than in
OVA/No, OVA/P.a and OVA/Bud/P.a mice.
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OVA/P.a, and OVA/Bud/P.a mice. This indicated that
OVA and P. aeruginosa caused lung tissues to secrete
AMPs. However, CRAMP expression was significantly
lower in OVA/Bud mice than in OVA-challenged mice
without inhaled budesonide (OVA/No mice). CRAMP
expression was significantly lower in OVA/Bud/P.a mice
than in OVA/P.a mice (Figure 4B). Thus, inhaled bude-
sonide reduced the production of CRAMP during the
antibacterial immune response to asthma.
Effects of budesonide on the antibacterial host defense of
lung epithelial cells
Allergic airway inflammation suppresses the innate anti-
microbial host defense [9]. However, whether inhaled
budesonide can attenuate the antibacterial host defense
in airway epithelial cells remains unclear. In our present
studies, MLE-12 cells were pretreated with budesonide.
We observed that budesonide increased the levels of
internalized GFP-labeled P. aeruginosa in MLE-12 cells
(Figure 5A). Total bacterial CFUs were significantly
higher in MLE-12 cells exposed to budesonide than in0
25
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Figure 5 In vitro effects of budesonide on the antibacterial host defen
budesonide, infected with GFP-labeled P. aeruginosa and observed by conf
lysed and plated to confirm the presence of intracellular bacteria. Bacteria
was determined by western blot analysis. D) MLE-12 cells were pretreated
to confirm the presence of intracellular bacteria. Bacteria were counted usi
neutralizing antibody. GFP-labeled P. aeruginosa were observed by confoca
respiratory infection due to P. aeruginosa.those exposed to PBS. The effect of budesonide on bac-
terial CFUs in MLE-12 cells was dose-dependent
(Figure 5B). High doses of budesonide (10-6 and 10-7 M)
induced significantly lower levels of CRAMP compared
with PBS or 10-8 M budesonide (P<0.01) (Figure 5C). Thus,
the role of CRAMP in antibacterial host defense may be
interesting. Incubation of MLE-12 cells with CRAMP-
neutralizing antibody induced significantly higher levels of
internalized GFP-labeled P. aeruginosa and bacterial CFUs
than incubation with isotype IgG antibody (Figure 5D, E).
This indicated that budesonide might attenuate the antibac-
terial host defense of airway epithelium cells by down-
regulating CRAMP (Figure 5F).
Discussion
Allergic asthma is a complex chronic inflammatory air-
way disease in which many immune cells such as mast
cells, eosinophils, T lymphocytes, macrophages, neutro-
phils, and epithelial cells and cellular elements play dif-
ferent roles. The Th2 hypothesis for asthma was first
proposed by Mosmann in 1989 [13]. He identified two




























se of airway epithelium cells. A) MLE-12 cells were pretreated with
ocal microscopy (original magnification ×400). B) MLE-12 cells were
were counted using drop plates. C) CRAMP expression in MLE-12 cells
with CRAMP neutralizing antibody. MLE-12 cells were lysed and plated
ng drop plates. E) MLE-12 cells were pretreated with CRAMP
l microscopy (original magnification ×400). F) Effects of budesonide on
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were reciprocally inhibitory. Th1 cells produce IFN-γ,
IL-2 and IL-12, which activate mechanisms important
for defense against viruses and bacteria [13]. Th2 cells
produce cytokines (IL-4, IL-5, IL-6, IL-9, and IL-13),
which are important in allergic inflammation and defense
against parasites. The Th2 hypothesis of asthma suggests
that an imbalance in Th1/Th2 immunity plays an import-
ant role in the pathogenesis of allergic asthma [15].
Inhaled corticosteroids (ICS) are recommended as a first-
line treatment for asthma by international guidelines.
However, a study conducted by Ma et al. showed that the
early application of glucocorticoids was a risk factor for
human enterovirus 71(HEV71) infection [16]. Recent
studies have also shown that topical glucocorticoids com-
promise the barrier function of normal skin, especially
during atopic dermatitis [17,18]. Jamieson et al. showed
that a sustained increase in serum glucocorticoid levels in
mice with influenza suppressed the systemic antibacterial
innate immune response [19]. In the present study,
inhaled budesonide decreased the extent of inflammation
and cellular infiltration in the airways and the level of IL-4
in OVA-challenged mice. Because allergic airway tissues
contain cytokines that promote bacterial infection and
colonization in asthma and other lung diseases, Th2 cyto-
kines may be relevant to infection in asthma patients [20].
However, OVA-challenged mice treated with inhaled
budesonide and exposed to P. aeruginosa were character-
ized by the extensive infiltration of numerous inflamma-
tory cells around bronchioles, alveoli, and blood vessels.
This indicated that inhaled budesonide increased lung in-
flammation, reduced the clearance of P. aeruginosa, and
increased the severity of pulmonary infection in OVA-
challenged mice exposed to P. aeruginosa. Infection with
P. aeruginosa was associated with increased levels of IL-4
in OVA-challenged mice treated with budesonide. Thus,
our study indicated that inhaled budesonide increased
lung infection in mice with allergic inflammation exposed
to P. aeruginosa, independent of levels of IL-4.
Airway epithelial cells secrete numerous antimicrobial
molecules that are part of the host’s first line of defense
against microbial invasion. Antimicrobial products secreted
constitutively and/or inducibly by epithelial cells include
lysozymes, lactoferrin, defensins, collectins, pentraxins,
cathelicidin, secretory leukocyte protease inhibitor (SLPI),
and serum amyloid A (SAA) [21]. Defensins and cathelici-
dins are primary AMP factors expressed in the lung and
secreted by airway epithelial cells, macrophages, neutro-
phils, and other classical host defense cells. Another recent
study demonstrated that IL-4 and IL-13 have an inhibitory
effect on antimicrobial activity of the airway epithelium, as
airway epithelial cells were unable to kill bacteria when
incubated with these cytokines [6]. Mice with allergic
airway inflammation showed significantly more viablebacteria in their lungs after infection. Th2-based inflamma-
tion was also found to suppress host defense and reduce
AMP expression in the skin [7,22]. Thus, the adaptive im-
mune system modulates the functions of the innate im-
mune system and allergic inflammatory diseases inhibit
antimicrobial host defense.
Inhaled corticosteroids are currently considered the
most effective means of reducing airway inflammation,
symptoms, and morbidity in patients with asthma. Glu-
cocorticoids were shown to affect the synthesis of anti-
microbial peptides in amphibian skin [23], inhibit NF-κB
signaling and induce immunosuppression in mammalian
cell cultures [24]. Mitchell et al. showed that bronchial
biopsy specimens from dexamethasone-treated calves had
significantly lower levels of tracheal antimicrobial peptide
mRNA expression than untreated controls. Thus, corti-
costeroids may impair innate pulmonary defenses through
the regulation of epithelial antimicrobial peptide expres-
sion [25]. Tomita et al. demonstrated that glucocorticoids
inhibited the release of β-defensin-2 stimulated by lipo-
polysaccharide in an airway cell line [26]. Aberg et al.
showed that psychological stress and systemic and topical
glucocorticoid therapy down-regulated epidermal anti-
microbial peptide expression and increased the risk of
extracutaneous infection in mice [27]. Roca-Ferrer et al.
demonstrated that glucocorticoid treatment could cause a
modest (30–40%) inhibition of spontaneous lactoferrin se-
cretion in cultured nasal and bronchial mucosa [28]. How-
ever, whether ICS can affect anti-microbial host defense
among asthma patients remains unclear. In the present
study, inhaled budesonide inhibited the production of
CRAMP in the antibacterial immune response of OVA-
challenged mice. AMP expression was localized to epithe-
lial cells in normal lung tissues and expressed in epithelial
cells and inflammatory cells in lung tissues of allergen-
challenged mice. Thus, inhaled budesonide suppressed
pulmonary antibacterial host defense in an asthmatic
mouse model and was dependent on AMPs.
Inhaled corticosteroids induced candidiasis in clinical
trials, but the association between the use of inhaled
corticosteroids in patients with asthma and the risk of
development of community-acquired pneumonia (CAP)
remains controversial.
P. aeruginosa is the leading pathogenic cause of detri-
mental chronic lung infections, and is a major determin-
ant of morbidity and mortality. Asthma patients with
bronchiectasis are not rare, and their conditions are often
exacerbated by P. aeruginosa status. Airway epithelial cells
play a critical role in the orchestration of innate defense
and inflammatory responses. P. aeruginosa can adhere to
airway epithelial cells and internalization has been observed
[29]. In the present study, budesonide increased the num-
ber of internalized P. aeruginosa organisms in MLE-12 cells
in vitro. The effect of budesonide on bacteria CFU in MLE-
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nificantly decreased CRAMP, which was associated with
antibacterial host defense.
Conclusions
We showed that inhaled budesonide could increase the
severity of P. aeruginosa infection in OVA-challenged
mice and attenuate antibacterial host defense in airway
epithelial cells by down-regulating CRAMP. These find-




BALB/c mice (weight 20 to 25 g and age 6 to 7 weeks)
were purchased from the Experiment Animal Center of
the Sichuan Academy of Medical Science. They were
maintained under standard conditions. All animal experi-
ments were performed in accordance with the guidelines
of the affiliated hospital of Luzhou Medical College animal
care and use committee. Pseudomonas aeruginosa strain
P. aeruginosa 103 was provided by the clinical laboratory
of the hospital affiliated with Lu Zhou Medical Collage.
MLE-12 was maintained in our lab. P. aeruginosa labeled
with green fluorescent protein (GFP) was provided by Dr.
Min Wu of the University of North Dakota (US).
Sensitization and challenge protocol
BALB/c mice were randomly grouped and sensitized
with intraperitoneal injections of 20 μg ovalbumin
(OVA) in 50 μl aluminum hydroxide on days 1 and 8.
Mice were challenged with intranasal instillation of
20 μg OVA in 50 μl phosphate-buffered saline (PBS) on
days 15 through 22 inclusive. Control mice were given
50 μl PBS.
Acute P. aeruginosa pneumonia model
OVA-challenged mice were treated with inhaled budeso-
nide (350 μg/kg) for 30 min every day from day 23
through 30 as previously described [30]. Twenty-four
hours after the last dose of inhaled budesonide and the
last OVA challenge, OVA-challenged mice were anesthe-
tized using diethyl ether. They were then infected intra-
nasally with 1×107 CFUs P. aeruginosa [31]. Control
mice received equivalent doses of PBS. Mice were eutha-
nized 24 hours after infection (Figure 1A).
Quantitation of bacteria
The lungs were removed, weighed, and homogenized in
10% fetal bovine serum (FBS) in Dulbecco’s modified
Eagle’s medium (DMEM), and aliquots were plated on
P. aeruginosa-selective plates. Bacterial colonies were
counted after incubation at 37°C for 24 hours, andimages were obtained using a Kodak Image Station
4000MM (USA).
Measurement of IL-4 and IFN-γ in serum
The levels of serum IL-4 and IFN-γ were determined
using an ELISA kit (R&D Systems, Minneapolis, MN,
USA) in accordance with the manufacturer’s instructions.
Histopathological analysis
Lung tissue was fixed in 4% paraformaldehyde for
24 hours at room temperature and embedded in paraf-
fin. Five-micrometer serial sections were cut and stained
with hematoxylin and eosin (HE) or subjected to immu-
nostaining. They were then observed using light micros-
copy. The degree of cellular infiltration was scored using
previously described methods [32]. Cellular infiltration
was scored from 0 to 4 as follows: 0 normal cells; 1 few
foci (minimal presence); 2 mild diffuse infiltration; 3
moderate diffuse infiltration; 4 severe diffuse infiltration.
Immunohistochemistry
The sections were deparaffinized and rehydrated. En-
dogenous peroxidase activity was blocked with 0.3%
hydrogen peroxide and the sections were incubated at
room temperature for 10 min. Antigen retrieval was per-
formed with citrate (pH = 6) at 95°C in an aqueous bath.
The process lasted 40 min. The sections were incubated
with rabbit polyclonal antibody against CRAMP (Abcam,
Cambridge, MA, USA) at 37°C for 45 min (1:300). The
secondary antibody (Envision™, DAKO, Denmark) was
applied (1:500) and incubated at 37°C for 45 min. Fi-
nally, the slides were visualized using DAB immunostain-
ing under a light microscope (Leica, Solms, Germany).
Preparation of P. aeruginosa for cell experiments
GFP-labeled P. aeruginosa was incubated overnight in
lysogeny broth (LB) culture medium on a shaking plat-
form at 150 rpm. The bacteria were added to 10 ml fresh
LB medium and cultured for 1 hour until the mid-log
phase. Optical density (OD) was measured at 600 nm.
When OD600nm reached 0.3, the bacteria were centri-
fuged at 8000 ×g for 5 minutes at 4°C. Bacteria were
washed three times in sterile PBS and the density was
adjusted to 0.1 OD (0.1 OD = 1 × 108 cells/ml) in sterile
Earle’s salt solution. Cells were infected with P. aerugi-
nosa at a 10:1 bacteria-cell ratio.
Cell culture and infection experiments
MLE-12 cells were incubated in 24-well tissue plates at
37°C and 5% CO2 in DMEM/F12 culture medium. The
cells were pretreated for 48 hours at 37°C with 10-6, 10-7,
and 10-8 M budesonide until they reached 85% conflu-
ence. Then 107 CFU ml−1 GFP-labeled P. aeruginosa was
added to MLE-12 cells. For antibody treatment, MLE-12
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medium for 24 hours. Then 10 μg/ml of CRAMP antibody
or a murine isotype control IgG was added to the cells
and incubated for 1 hour. MLE-12 cells were infected with
107 CFU ml−1 GFP-labeled P. aeruginosa. After incubation
for 1 hour, the cells were washed with PBS and incubated
with fresh medium containing polymyxin 50 μg ml−1 to
kill extracellular bacteria. After 1 hour, the culture media
was removed and samples were plated in LB solid culture
medium to confirm that the extracellular bacteria had
been killed. The 24-well plates were observed using a
Zeiss 510 META confocal microscope (Zeiss, Gottingen,
Germany). The cells were then homogenized with PBS
and spread on LB plates to determine levels of intracellu-
lar bacteria. The plates were cultured at 37°C overnight,
and colonies were counted. Duplicates were made for each
sample and control [33,34].
Western blot
Lung tissue and MLE-12 cells were homogenized in lysis
buffer (1000 μl RIPA with 10 μl phenylmethanesulfonyl-
fluoride (PMSF), Beyotime, China). To ensure each sam-
ple contained equal amounts of protein, a protein assay
was performed using a bicinchoninic acid (BCA) con-
centration measurement kit (Beyotime, China). Twenty
micrograms of protein was loaded per lane and then run
on 15% sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) at 100 V for 90 min. Dissolved
proteins were transferred onto a nitrocellulose membrane
by electroblotting with an Amersham Ecl Semi-Dry Trans-
fer Unit (15 V for 20 min). Non-specific binding sites were
blocked with western confining liquid (Beyotime, China)
at 37°C for 1 hour. Rabbit polyclonal antibody against
CRAMP (1:500 dilution) was applied to the membranes
and incubated overnight at 4°C. The membranes were
washed three times in PBS for 10 min each. They were
then incubated with HRP-conjugated goat anti-rabbit
antibody (1:800 dilution, Beyotime, China) at 37°C for
1.5 hours and washed three times for 10 min each. Chemi-
luminescent substrate (Beyotime, China) was added to the
membrane and exposed strips were evaluated using a
Kodak Image Station 4000MM (US).
Statistical analysis
Data are expressed as mean ± standard error. Statistical
analysis was performed using ANOVA (Tukey’s post
hoc) or Student’s t-test and the level of significance was
defined as P<0.05 between any two groups. The data
were analyzed using SPSS 13.0 software.
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